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ABSTRACT 
Diabetes is an increasingly common disease with an important negative impact on patient’s morbidity 
and mortality, being the main cause of end stage renal disease. Management of the diabetic patient with 
chronic kidney disease poses additional challenges, namely with respect to defining glycaemic targets and 
in the therapeutics employed to achieve them. The authors review the state of the art evidence about the 
use of antihyperglycaemic agents in type 2 diabetes, from the perspective of a chronic kidney disease 
patient’s health care provider.
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RESUMO 
A diabetes é uma patologia com uma prevalência crescente, que condiciona um importante impacto 
negativo na morbilidade e mortalidade dos doentes, sendo a principal causa de doença renal crónica ter-
minal. O tratamento da diabetes no doente com doença renal crónica implica desafios adicionais nomea-
damente em relação à definição dos alvos glicémicos e da terapêutica utilizada para os atingir. Os autores 
fazem uma revisão sobre o estado da arte da utilização dos agentes hipoglicimiantes na diabetes tipo 2 
na perspectiva do profissional de saúde responsável por doentes com doença renal crónica.
Palavras -chave: Agentes hipoglicemiantes; diabetes; doença renal crónica
Management of hyperglycaemia 
in type 2 diabetic patients 
with Chronic Kidney Disease
Tratamento da hiperglicémia nos doentes diabéticos 
tipo 2 com Doença Renal Crónica
Sílvia Coelho, Patrícia Carrilho, Luís Inchaustegui
Department of Nephrology, Hospital Fernando da Fonseca EPE, Amadora, Portugal
Received for publication: 13/03/2013
Accepted in revised form: 08/05/2013
ORIGINAL ARTICLE
Port J Nephrol Hypert 2013; 27(2): 91-100
Advance Access publication 20 May 2013
Nefro - 27-2 - MIOLO.indd   91 26-06-2013   15:08:15
92    Port J Nephrol Hypert 2013; 27(2): 91-100
CMYKP
INTRODUCTION 
Diabetes is a global public health problem and 
epidemiologists estimate an increase in world preva-
lence from 6.4% to 7.7% in the next 20 years, 
accounted particularly by developing countries1. In 
Portugal, the prevalence of diabetes was estimated 
at 11.7%, being more frequent in men (14.2%) than 
women (9.5%) and increasing with age2.
Diabetes has an important negative impact in 
morbidity and mortality, remaining a leading cause 
of cardiovascular disorders, blindness, amputations, 
and hospitalizations3. Data suggest that the risk of 
nephropathy is currently equivalent in the two types 
of diabetes, affecting approximately one third of 
diabetics and being the most common cause of end-
-stage renal disease (ESRD) worldwide4.
The treatment approach to diabetes should be 
multidisciplinary, implying lifestyle modifications, 
control of body weight, blood pressure, dyslipidae-
mia, associated comorbidities and, of course, glycae-
mic blood values3. It poses an increasing economic 
burden in an increasingly economically fragile soci-
ety, and optimization of resources is mandatory.
Chronic kidney disease (CKD) patients, for reasons 
that will be detailed below, have contraindications 
to many of the currently available oral antihyperg-
lycaemic agents, making glycaemic control even 
more challenging. Knowledge of these absolute and 
relative contraindications allows us to make a more 
rational use of the available drugs, achieving the 
most favourable risk/benefit profile and, concomi-
tantly, better clinical outcomes.
In this paper, we will review the optimal glycaemic 
targets for the CKD type 2 diabetic patient and dis-
cuss the therapeutics currently available to achieve 
them.
 WHAT IS THE GLYCAEMIC GOAL  
IN CKD PATIENTS?
Two primary techniques are available to assess 
the effectiveness of the management plan on gly-
caemic control: self -monitoring of blood glucose and 
haemoglobin A1c3.
Evidence that achieving an haemoglobin A1c 
(HbA1c) level of 7.0% is able to prevent the micro-
vascular complications of types 1 and 2 diabetes in 
the general population, has long been evident from 
studies, such as the Diabetes Control and Complica-
tions Trial (DCCT)5 and the United Kingdom Prospec-
tive Diabetes Study (UKPDS)6, 7. Three recent studies 
(ADVANCE, ACCORD, VADT)8 -10 have revealed that 
even more intensive glycaemic control (HbA1c 6.5%) 
further reduces the development of elevated albu-
minuria in patients with type 2 diabetes, although 
none showed significant benefits on creatinine -based 
estimates of glomerular filtration rate (eGFR).
Less is known about appropriate glycaemic control 
in patients with diabetes and more advanced CKD, 
because no prospective, randomized clinical trials 
evaluating the level of glycaemic control on health 
outcomes have been carried out in patients with CKD 
stages 3 -5. Nevertheless, several observational stud-
ies showed that higher levels of haemoglobin A1c 
were associated with higher death rates in patients 
with diabetes and chronic kidney disease after adjust-
ing for markers of inflammation and malnutrition11, 
12. Therefore, although there is need for a much bet-
ter understanding of the CKD -related characteristics 
of diabetes mellitus, glycaemic control can still be 
argued to be beneficial in preventing complications, 
even in dialysis -dependent patients13.
However, another important factor to be taken 
into account is the inaccuracy of the HbA1c measure-
ment in reflecting serum glucose concentrations in 
this population. Studies have shown that glucose 
levels in CKD patients are higher than expected for 
given HbA1c levels, and this is most marked in those 
on dialysis14, 15. Factors that may contribute to 
falsely decreased values of HbA1c include a reduced 
red blood cell lifespan, transfusions, and haemolysis. 
On the other hand, falsely increased values may 
occur, less commonly, due to carbamylation of the 
haemoglobin and acidosis16.
Therefore, when targeting for the ideal HbA1c in 
our CKD patients (mainly those on stages 4 and 5), 
we should bear in mind that a result of 6.5% may 
be equivalent to a higher value. However, care not 
to “overtreat” hyperglycaemia is particularly impor-
tant in a population at increased risk of hypoglycae-
mia: they have a decreased clearance of insulin and 
of most oral agents used to treat diabetes; renal 
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gluconeogenesis is impaired with reduced kidney 
mass; and many advanced CKD patients are frail, 
malnourished, non -ambulatory and may be less able 
to respond appropriately to hypoglycaemia17.
Although alternatives to HbA1c have been searched 
(i.e., glycated albumin, which reflects glycaemic 
control over a shorter period16), it still remains the 
best clinical marker of long -term glycaemic control 
despite its limitations, particularly if combined with 
self -monitoring of blood glucose.
In light of this knowledge, the last update of 
KDOQI recommendations (2012) first introduced the 
notion of individualized HbA1c targets. They recom-
mended: 1) a target HbA1c of~ 7.0% to prevent or 
delay progression of the microvascular complications 
of diabetes; 2) not treating to an HbA1c target of < 
7.0% in patients at risk of hypoglycaemia (advanced 
CKD patients were considered to be included in this 
group); 3) target HbA1c be extended above 7.0% in 
individuals with co -morbidities or limited life expect-
ancy and risk of hypoglycaemia16.
 WHAT IS THE BEST THERAPEUTIC  
APPROACH?
Metformin has long been recommended as the 
initial pharmacological therapy for type 2 diabetes, 
in the absence of specific contraindications, along 
with lifestyle interventions. This position has not 
been changed in the last guidelines16. However, the 
consensus algorithm for the initiation and adjust-
ment of therapy proposed by the American Diabetes 
Association (ADA) and the European Association for 
the Study of Diabetes published in 2012 was less 
prescriptive than prior algorithms with respect to 
second line therapies. The limited data on this issue 
was acknowledged and combination therapy with 
additional oral or injectable agents was considered 
reasonable, with the specific choice based on an 
integrated approach to the patient (medical, social 
and economical factors)18. Insulin is still frequently 
used, due to the progressive β  -cell dysfunction that 
characterizes type 2 diabetes18.
Diabetic patients with chronic kidney disease 
(CKD) have more limited therapeutic options. The 
most important reason is because a reduced GFR 
may lead to the accumulation of renally excreted 
drugs and/or their metabolites and this can induce 
severe side effects. Moreover, uraemia differentially 
affects absorption and metabolic pathways in the 
gastrointestinal tract and liver and, therefore, can 
change the systemic bioavailability of drugs in a not 
always predictable way. The hypoalbuminaemia com-
monly seen in CKD patients may also interfere with 
protein binding -drugs total clearance and half-
-life19.
For these reasons, insulin therapy was previously 
commonly seen as the (only?) agent of choice to 
achieve glycaemic control in patients with CKD. 
However, and albeit the persistent lack of evidence 
in this field, several agents, including some of the 
most recent drugs available, were found to be effec-
tive and safe even in patients on dialysis and may 
be useful therapeutic options in this population.
In the next section, we will review the available 
hypoglycaemic agents from the perspective of a type 
2 diabetic CKD patient’s health care provider. Table I 
and figure 1 provide a practical summary of the 
mechanism of action, advantages, adverse effects 
and use in renal failure of antihyperglycaemic agents, 
discriminating those currently commercially available 
in Portugal.
BIGUANIDES 
Nowadays, metformin is the only commercially 
available biguanide used in the treatment of diabe-
tes, having been first introduced in the UK in 1957. 
It acts by improving insulin sensitivity what, conse-
quently, decreases hepatic gluconeogenesis and 
enhances peripheral glucose uptake. Importantly, it 
does not increase the risk of hypoglycaemia20.
Metformin is recommended as the first line the-
rapy for diabetes by the international consensus 
guidelines due to its efficacy combined with a favou-
rable side effect profile and low cost3, 16. The UK 
Prospective Diabetes Study first revealed its supe-
riority by showing a lower mortality from cardiovas-
cular disease in overweigh patients with diabetes 
treated with metformin rather than sulphonylureas 
or insulin7. Metformin is mainly associated with 
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minor gastrointestinal symptoms (anorexia, nausea, 
vomiting, diarrhoea and abdominal pain) and it may 
impair absorption of vitamin B12 and folic acid20. 
However, it is the perceived risk of lactic acidosis in 
the presence of renal, hepatic, respiratory, or cardiac 
failure that remains one of the most important causes 
Table I
Antihyperglycaemic agents
Agent 
(mechanism)
Advantages Adverse effects CKD stage 3 CKD stage 4-5d 
Biguanides (Improve insulin sensitivity)
– Metformin – No weight gain
– No hypoglycaemia
–  Reduction in cardiovascular 
events and mortality
– Gastrointestinal side effects
– Lactic acidosis
– VitB12 deficiency
– Caution – Avoid 
Sulfonylureas – 2nd generation (Increase insulin secretion by pancreatic beta cells)
– Glibenclamide 
– Glipizin 
– Gliclazide 
– Glimepiride 
– Well tolerated
–  Reduction in cardiovascular 
events and mortality
– Hypoglicaemia risk
– Weight gain
–  May blunt myocardial 
ischaemic preconditioning
–  Effectiveness decreases over 
time
–  Glipizide and gliclazide: no 
dose adjustment necessary
– Glibenclamide: avoid 
– Glimepiride1: start at 1mg/daily
–  Glipizide and gliclazide: no 
dose adjustment necessary
– Glibenclamide: avoid 
– Glimepiride: avoid
Meglitinides (Increase insulin secretion by pancreatic beta cells)
– Repaglinide*
– Nateglinide 
– Mitiglinide* 
–  Decreases post-prandial 
hyperglycaemia
–  Hypoglycaemia risk
–  Weight gain
–  May blunt myocardial 
ischaemic preconditioning
–  Frequent dosing schedule 
–  Repaglinide1: start at 0.5mg 
with meals
–  Nateglinide1: start at 60mg 
with meals
–  Mitiglinide1: no dose 
adjustment necessary
–  Repaglinide1: start at 0.5mg 
with meals
–  Nateglinide: avoid in CKD 5
–  Mitiglinide1: start at 5mg with 
meals
Alpha-Glucosidase inhibitors  (Slows intestinal carbohydrate digestion and consequent absorption)
–  Acarbose 
–  Miglitol*
–  Voglibose*
–  Nonsystemic medication
–  Reduces postprandial 
glycaemia
–  Gastrointestinal side effects 
–  Dosing frequency
–  No dose adjustment necessary –  Avoid 
Thiazolidinediones (Improve insulin sensitivity)
–  Pioglitazone 
–  Rosiglitazone*+
–  No hypoglycaemia
–  Pioglitazone also ↑ HDL 
cholesterol and ↓ Triglycerides 
–  Weight gain
–  Oedema
–  Heart failure
–  Bone fractures
–  No dose adjustment necessary –  No dose adjustment necessary
DPP-4 Inhibitors (Incretin enhancers)
–  Sitagliptin 
–  Vidalgliptin 
–  Saxagliptin 
–  Linagliptin
–  No hypoglycaemia
–  No effect on weight 
–  May cause urticaria/
angioedema
–  Cases of pancreatitis observed
–  Long-term safety unknown
–  Sitagliptin2: 50mg/d 
–  Vidalgiptin2: 50mg/d 
–  Saxagliptin2: 2.5mg/d
–  Linagliptin: no dose 
adjustment necessary
–  Sitagliptin: 25mg/d 
–  Vidalgiptin: 50mg/d
–  Saxagliptin: 2.5mg/d
–  Linagliptin: no dose 
adjustment necessary
Incretin Mimetics  (GLP-1 receptor agonists)
–  Exenatide*
–  Liraglutide*
–  Weight reduction
–  Potential for improved b-cell 
mass/function
–  Gastrointestinal side effects 
–  Cases of acute pancreatitis 
observed
–  C-cell hyperplasia/ medullary 
thyroid tumours in animals
–  Injectable
–  Long-term safety unknown
–  Exenatide: dose reduction2,3
–  Liraglutide: avoid (insufficient 
safety data)
–  Exenatide: avoid
–  Liraglutide: avoid (insufficient 
safety data)
Insulin (increases glucose uptake by the liver and peripheral tissues)
–  Rapid-acting, 
long-acting, 
premixed
–  Universally effective 
–  Unlimited efficacy, in theory
–  Decreases microvascular risk
–  Hypoglycaemia risk
–  Weight gain
–  Injectable
–  No advised dose adjustment 
(adjust dose based on patient 
response)
–  No advised dose adjustment 
(adjust dose based on patient 
response)
* Not commercially available in Portugal. Data from www.infarmed.pt updated in April 2013; +Contraindicated due to increased myocardial infarction risk; 1 no data available about 
the maximum recommended dose; 2 no dose adjustment necessary if eGFR >50ml/min/1.73m2; 3 no data available about the percentage of dose reduction. 
CKD stage 3: eGFR 30-59ml/min/1.73m2; CKD stage 4: eGFR 15-29 ml/min/1.73m2; CKD stage 5: eGFR <15ml/min/1.73m2; CKD stage 5d: on dialysis.
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for patients being denied this medication21. Metformin 
associated lactic acidosis (MALA) is defined as the 
presence of lactic acidosis associated with a lactate 
> 5mmol/l in a patient medicated with metformin22.
Most of the evidence for the association between 
biguanides and lactic acidosis is historical data from 
phenformin21. Phenformin was in fact withdrawn 
from the market because of an association with fatal 
lactic acidosis, which was calculated to be 10 -20 
times greater than for metformin20. The physiopa-
thology of MALA is complex and mostly unclear. 
Metformin has been proposed to increase lactate 
production through an intracellular shift to anaerobic 
metabolism and impair lactate clearance by the 
liver23. This would become particularly relevant in 
cases of accumulation of metformin (i.e., in renal 
insufficiency, as the drug main route of elimination 
is renal tubular secretion) or increased lactate pro-
duction (i.e., inadequate tissue delivery of oxygen 
or excessive tissue oxygen demand).There are many 
published case reports that describe an association 
between metformin and lactic acidosis22, 24 -26. 
However, they have been highly criticised because 
it remains difficult to establish the exclusive role of 
metformin as the cause of lactic acidosis, as most 
patients were admitted with other causes of increa-
sed lactate, such as sepsis, dehydration or cardiac 
heart failure. Moreover, the lack of a relation 
between lactic acid/metformin concentrations and 
mortality and the absence of an association between 
metformin concentration and lactic acid concentra-
tion (that was proved to exist in the case of phen-
formin) made some investigators suggest that the 
association between lactic acido sis and metformin 
is coincidental27 -29.A Cochrane review of 206 com-
parative trials and cohort studies in patients with 
type 2 diabetes who were treated with metformin, 
found no evidence of increased risk of develop ing 
fatal or non -fatal lactic acidosis in the subgroup of 
metformin treated patients. However, these studies 
did not include patients who had contraindications 
for the use of metformin and so nothing could be 
concluded about the risk of MALA in this subpopu-
lation30. Nevertheless, there are clinical studies that 
corroborate the association of metformin with higher 
lactate levels. A Chinese study describes the result 
of a cross sectional measurement of lactate in 1024 
diabetics in an outpatient clinic that had normal 
renal function and no increased risk of elevated 
lactate (i.e., excluded patients with chronic liver 
disease and cardiac insufficiency). They showed that 
patients medicated with metformin had a slightly 
but significant higher level of lactate than patients 
who were not on this medication31. Another retros-
pective French study compared patients admitted to 
an intensive care unit for MALA who had an inten-
tional versus accidental intoxication with metformin. 
They showed that metformin can, in fact, lead to 
lactic acidosis, although mortality was primarily 
associated with underlying health status and organ 
dysfunction32.
In conclusion, causality between metformin and 
lactic acidosis cannot be ruled out, although its real 
impact in the prognosis and morbidity/mortality of 
diabetic patients is difficult to account for. The 
challenge is to differentiate who would benefit from 
being denied the first line medication for diabetes. 
The European, American, Canadian and many other 
national guidelines agree to contraindicate metfor-
min in patients with CKD class 4 or higher and most 
suggest a cautious use in CKD class 316, 18, 33. While 
there are no randomized controlled trials (RCTs) that 
evaluate the safety and potential benefit of this 
medication, all patients should be educated to con-
tact a health care provider and hold metformin (as 
well as angiotensin -converting enzyme inhibitor, 
angiotensin II receptor blockers, diuretics, and non-
-steroidal anti -inflammatory drugs), if diarrhoea or 
Figure 1
Mechanism of action of hypoglycaemic agents. Colours filling the boxes rep-
resent drugs that may be used in chronic kidney disease patients: green, may 
be used in CKD stage 3 -5d (although some may need dose adjustment - con-
sult table I); orange, may be used in CKD stage 3 only; and red, cannot be 
used in any stage of CKD. Boxes with more than one colour mean indications 
of use in renal failure patients for different drugs in the same class.
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vomiting together with inability to tolerate oral 
liquids intake develops24.
SULFONYLUREAS 
Sulfonylureas reduce blood glucose by stimulating 
the pancreatic beta cells to increase insulin secre-
tion34. Therefore, their effectiveness tends to decline 
over time, as there is a reduction in the number of 
viable pancreatic beta cells35. The major risk asso-
ciated with its use is hypoglycaemia19.
The first -generation sulfonylureas (acetohexamide, 
chlorpropamide, tolazamide and tolbutamide), the 
oldest oral hypoglycaemic agents, are almost exclusively 
excreted by the kidney and are, therefore, contraindi-
cated in CKD due to the risk of hypoglycaemia16.
Second -generation agents (gliclazide, glimepiride, 
glipizide and glibenclamide) are metabolized in the 
liver, but some of the drugs (glimepiride and gliben-
clamide) excrete their active metabolites in the urine 
and, therefore, should be avoided in renal failure. 
Glipizide and gliclazide are the preferred agents and 
do not need dose adjustment16, 19. They are primarily 
metabolized in the liver and although more than 
60% of their metabolites are excreted in the urine, 
these have no hypoglycaemic activity19.
MEGLITINIDES 
Meglitinides are insulin secretagogues that stimu-
late pancreatic beta cells. Compared with sulfonylureas 
they are shorter -acting, have modest glycaemic efficacy 
and a relatively low risk of hypoglycaemia18.
There are three meglitidines (nateglinide, repagli-
nide, and mitiglinide) currently in clinical use but 
only nateglinide is available in Portugal19. Although 
hypoglycaemia has not been demonstrated to incre-
ase substantially with progressive falls in GFR, renal 
dose adjustment is recommended as drug accumu-
lation (repaglinide) or of their active metabolites 
(nateglinide and mitiglinide) can occur in renal 
failure36 -38. Accumulation of active metabolites is 
particularly notorious with nateglinide, that should 
therefore be avoided in ESRD19.
ALPHA -GLUCOSIDASE INHIBITORS 
The antihyperglycaemic action of alpha -glucosidase 
inhibitors (acarbose, miglitol and voglibose) results 
from the reversible inhibition of membrane -bound 
intestinal alpha -glucoside hydrolase enzymes. Alpha-
-glucosidase inhibitors decrease the rate of breakdo-
wn of complex carbohydrates so that less glucose 
is absorbed and postprandial hyperglycaemia is 
lowered19.
Acarbose is metabolized exclusively within the 
gastrointestinal tract and approximately a third of 
these metabolites are absorbed and subsequently 
excreted in the urine, one of them with alpha-
-glucosidase inhibitory activity. Although normally 
less than 2% of the total administered dose is 
excreted in the urine as active drug, patients with 
severe renal impairment (creatinine clearance < 25 
mL/min) can attain peak plasma concentration of 
acarbose about 5 -fold higher39.
Miglitol is absorbed without metabolization and is 
eliminated by renal excretion as unchanged drug40.
As these drugs act locally, dose adjustment to 
correct for the increased plasma concentrations is 
not feasible19. Although important adverse side 
effects have not been described, data are scarce and 
its generalized use in advanced renal failure is not 
recommended16, 41.
THIAZOLIDINEDIONE 
Thiazolidinediones (TZDs) are peroxisome prolife-
rator–activated receptor gamma (PPARγ) agonists 
that improve insulin sensitivity in skeletal muscle 
and reduce hepatic glucose production42. They do 
not increase the risk of hypoglycaemia and may be 
more durable in their effectiveness than sulfonylu-
reas and metformin18.
There are currently two available agents from this 
class: pioglitazone and rosiglitazone. Pioglitazone, 
which seems to also act like a partial PPARα agonist, 
appears to decrease triglycerides, increase HDL 
cholesterol and have a modest benefit on cardio-
vascular events42, 43. Rosiglitazone, an apparently 
pure PPARγ agonist, is no longer widely available 
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owing to concerns of increased myocardial infarction 
risk44,45.
Drugs in this class do not need renal dose adjust-
ment because they have predominant hepatic meta-
bolism and their pharmacokinetic profile is indepen-
dent of renal function46, 47. However, because their 
side effect profile includes weight gain, fluid reten-
tion that may lead to oedema and/or heart failure, 
and increased risk of bone fractures, they should be 
used with caution in the chronic kidney disease 
population3, 16, 18. Moreover, pioglitazone has been 
associated with a possible increased risk of bladder 
cancer48.
DPP -4 INHIBITORS 
The oral dipeptidyl peptidase 4 (DPP -4) inhibi-
tors decrease the breakdown of the incretin hor-
mones, such as glucagon -like peptide 1 (GLP -1). 
GLP -1 is an intestinal hormone with a meal -induced 
secretion that stimulates insulin secretion and 
suppresses glucagon release in a glucose -dependent 
manner49.
They are generally well tolerated, weight neutral 
and do not cause hypoglycaemia3, 18. All can be 
used in CKD patients, but sitagliptin, saxagliptin, 
and vildagliptin need dose adjustments, as oppo-
sed to linagliptin that can be used in the normal 
doses16.
INCRETIN MIMETICS 
Incretin mimetics (exenatide and liraglutide) are 
subcutaneously injectable GLP -1 receptor agonists 
that thereby stimulate pancreatic insulin secretion 
and suppress pancreatic glucagon output in a glu-
cose dependent manner, slow gastric emptying, and 
decrease appetite19. Their main advantage is weight 
loss18. Exetanide has a renal excretion and should 
be avoided in patients with eGFR < 30ml/min/1.73m2 
16. Liraglutide is not significantly eliminated by the 
kidneys and pharmacokinetic studies suggest blood 
levels are not affected by renal failure50. However, 
there is still insufficient safety data to recommend 
its use in CKD patients16.
 SODIUM -GLUCOSE CO -TRANSPORTER  
2 (SGLT2) INHIBITORS
SGLT2 inhibitors are the most recent class of 
drugs approved by the United States Food and 
Drug Administration (FDA) for the treatment of 
diabetes, still not available in Portugal. They are 
currently represented by canagliflozin and impro-
ve glycaemic control in an insulin -independent 
fashion through inhibition of glucose reuptake in 
the kidney51.
Phase III clinical trials have shown improved 
glycaemic control in type 2 diabetes associated 
with a relatively low hypoglycaemia risk and weight 
loss -promoting effect. The major side effects appe-
ar to be urinary and mycotic genital infections and 
adverse effects related to osmotic diuresis and 
reduced intravascular volume51, 52.A phase III RCT 
with canagliflozin against placebo was performed 
in 272 CKD 3 patients, concluding that this new 
agent was generally well tolerated and might be 
a possible therapeutic option for this subpopula-
tion. However, they did report a higher decrease 
in eGFR at 26 weeks in the canagliflozin arm com-
pared to placebo, for which statistical significance 
was not performed. While data are still scarce, 
caution should be taken before using them in CKD 
patients53.
 OTHER NON -INSULIN  
HYPOGLYCAEMIC DRUGS
There are many other agents that are being inves-
tigated as potential therapeutic weapons in diabetes. 
Bile acid sequestrants (i.e., colesevelam)54, dopamine -2 
agonists (i.e., bromocriptine)55 and amylin mimetics 
(i.e., pramlintide)56 are some of the most promising 
drugs that are now defining their potential role in the 
treatment of diabetes.
INSULIN 
Exogenous insulin is the most potent antihyper-
glycaemic agent, with a theoretically universal and 
unlimited effectiveness. However, because it is an 
injectable drug associated with hypoglycemia risk 
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and weight gain, it is most commonly considered a 
second or third line therapy18.
Due to the progressive Beta -cell dysfunction that 
characterizes type 2 diabetes, insulin replacement 
therapy is frequently required, alone or in combina-
tion with other agents18. This is particularly true in 
the renal failure population, where the therapeutic 
options are more limited.
There are a variety of insulin preparations, which 
specific indications and pharmacokinetics go beyond 
the scope of this review. None of them is contrain-
dicated in CKD patients and dose should be adjusted 
based on patient response16. Due to the fact that 
the kidneys metabolize 25% of circulating insulin, 
progressive declines in eGFR are expected to incre-
ase the exogenous (and residual endogenous) blood 
levels and thus decrease the requirement dose of 
exogenous insulin41.
 SUGGESTED SCHEDULES  
IN THE RENAL FAILURE PATIENT
Guidelines for the treatment of diabetes are beco-
ming less strict and, as previously stated, should be 
based upon clinical, social and economical criteria18. 
Having this in mind, and according to the review 
above, we recommend the use of the following drugs 
in chronic kidney disease patients in monotherapy 
or, if necessary, in 2 or 3 drug -combinations:
• CKD 3: Metformin + second generation sul-
phonylureas (gliclazide or glipizide)/meglitidines 
(any) + DPP4 inhibitors (any)/Incretin mimetics 
(exenatide) + Thiazolidinediones (pioglitazone) 
+ alpha -Glucosidase inhibitors (any) + insulin.
• CKD 4 -5d: Second generation sulphonylureas 
(gliclazide or glipizide)/Meglitidines (repaglidine 
or mitiglinide) + DPP4 inhibitors (any) + Thia-
zolidinediones (pioglitazone) + insulin.
The order does not mean to indicate any specific 
preference. However, clinicians should not forget the 
advantages and possible side effects of each class 
of drugs when prescribing. Namely, thiazolidinedio-
nes can cause fluid retention, heart failure and bone 
fractures and, therefore, may be contraindicated in 
the subgroup of renal failure patients with cardio-
vascular and/or mineral bone disease. Additionally, 
renal patients that have previously been exposed to 
cyclophosphamide would have a cumulative risk of 
bladder cancer if given rosiglitazone. Metformin 
should be used cautiously, as explained in the for-
mer section. When prescribing drug combinations, 
agents with the same mechanism of action should 
not be favoured (these agents are separated above 
by a slash).
CONCLUSION 
Diabetic patients with chronic kidney disease are 
a particular challenging population to treat. While 
glycaemic targets are still not well validated, HbA1c 
and daily finger -stick blood glucose measurements 
seem to be the most reasonable measure of glyca-
emic control. Metformin, the fist -line therapeutic 
agent in the general population, should be used 
with caution in CKD class 3 and is contraindicated 
when eGFR < 30ml/min/1.73m2. Alternatives to be 
used alone or in combination, without dose adjust-
ment, include some second generation sulphonylu-
reas, thiazolidinediones and insulin. Nevertheless, 
thiazolidinediones may cause oedema and heart 
failure and should be used with caution in this 
population. Meglitinides, DPP -4 inhibitors and some 
incretin mimetics can also be used with dose 
adjustment.
In conclusion, although there are still many open 
questions about the ideal treatment of diabetic CKD 
patients, there are now many available therapeutic 
options, that if used with knowledge, can improve 
the quality and quantity of life of these patients.
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